LOS ANGELES, June 13, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR IOVANCE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS T ...

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/iovance-biotherapeutics-inc- ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=152606&from=3 C ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

公司事件 - Iovance Biotherapeutics公司因涉嫌在2024年5月9日至2025年5月8日期间向投资者发布虚假或误导性声明被集体诉讼 [1] - 公司被指控隐瞒关键不利事实，包括其实际增长潜力不足、无法通过获批治疗中心网络有效推动治疗需求 [1] - 2024年7月25日公司发布2024年第二季度财报，同时下调全年收入指引，归因于：1）治疗中心设备年度维护导致产能减少超50%持续约1个月 2）Proleukin销售额低于预期 3）治疗中心患者收治速度不稳定 [1] 股价影响 - 2025年5月8日至9日公司股价从3.17美元/股暴跌44.795%至1.75美元/股，创单日最大跌幅 [1] 法律程序 - 股东集体诉讼截止日期为2025年7月14日，受损投资者可通过指定链接登记参与 [2] - 登记股东将获案件进展监控服务，无需支付费用即可参与诉讼 [2]

Iovance Biotherapeutics (IOVA) FY 2025 Conference June 11, 2025 01:20 PM ET Speaker0 Good afternoon everyone. Thanks so much for joining us. I'm really pleased to be joined by Brian Gasman, EVP of Medical Affairs, and Dan Kirby, CCO of Iovance. Thank you both for joining us. Speaker1 Thank you. Speaker0 Dan, maybe I can start with you here. Given Amtagni has been on the market now for over a year, what have been the biggest learnings from this launch? And what has been maybe easier in some ways, or what has ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeutic ...

Iovance Biotherapeutics (IOVA) FY 2025 Annual General Meeting June 10, 2025 11:00 AM ET Speaker0 Good morning. Will the meeting please come to order? My name is Ian Dukes, and I'm the chairman of the board of directors of Iovas Biophy Biotherapeutics Incorporated. I'm pleased to welcome all of you to this annual meeting of the stockholders of Iovance Biotherapeutics. This meeting is being held virtually through a live webcast. Several Iovance directors and executive officers are attending stage meeting virt ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...